Clopidogrel PCD Pharma Franchise Company
Cafoli Lifecare offers a Clopidogrel range of 15 formulations in tablets and capsules, manufactured in WHO-GMP certified facilities. Distributors building a cardiac portfolio can secure district-wise monopoly franchise rights on this essential antiplatelet molecule.
What is Clopidogrel?
Clopidogrel is an antiplatelet agent that irreversibly blocks the P2Y12 ADP receptor on platelets, preventing platelet aggregation and reducing the risk of arterial thrombosis. It is listed on the WHO Model List of Essential Medicines. More information is on MedlinePlus.
Therapeutic Applications
Clopidogrel is used in acute coronary syndrome, after myocardial infarction and ischemic stroke, and following coronary stent placement, often combined with aspirin as dual antiplatelet therapy. Prescribers include cardiologists, neurologists and consultant physicians.
Why Clopidogrel is a High-Potential Molecule for Distributors
Cardiovascular disease is India's leading cause of mortality, and clopidogrel is standard secondary-prevention therapy taken for months to lifelong after every stent, heart attack or stroke. Fixed-dose combinations with aspirin and atorvastatin bundle a cardiac patient onto a single prescription, delivering high-value, long-duration repeat business for franchise partners.
Why Choose Cafoli Lifecare
Cafoli Lifecare is a WHO-GMP compliant, DCGI-approved PCD pharma company with 1000+ franchise partners across India. Partners receive district-wise monopoly rights, promotional inputs including visual aids, MR bags and product cards, and consistent stock availability backed by quality-tested manufacturing.
References
- MedlinePlus: Clopidogrel
- PubChem: Clopidogrel
- WHO Model List of Essential Medicines
Our formulations of Clopidogrel find application in many critical therapeutic areas. Its therapeutic spectrum includes, but is not limited to: